Merck and Moderna announced today the initiation of the Phase 3 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in Combination with KEYTRUDA® (pembrolizumab) after neoadjuvant KEYTRUDA and chemotherapy in patients with certain types of non-small cell lung cancer (NSCLC). Read more: https://lnkd.in/ezG4A7hR
Moderna
Biotechnology Research
Cambridge, Massachusetts 628,160 followers
Our mission is to deliver the greatest possible impact to people through mRNA medicines.
About us
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. To learn more, visit www.modernatx.com. This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).
- Website
-
https://www.modernatx.com/?tc=soc_7y8qkt&cc=1004
External link for Moderna
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2010
- Specialties
- Biotechnology and mRNA Therapeutics
Locations
-
Primary
200 Technology Sq
Cambridge, Massachusetts 02139, US
-
1 Upland Rd
Norwood, Massachusetts 02062, US
Employees at Moderna
-
Jean-Christophe Wüthrich
Business Technology Management | Strategic Planning & IT Governance | Service Management, Integration & Performance | Change Management | Sourcing…
-
Shawn Lipstein
Innovative UX & Product Leader | Critical Thinker | Strategic Visionary | Empathetic Manager | Driven Partner | Crystal Clear Communicator
-
Lukasz Wielochowski
Head of Moderna Enterprise Solution Hub in Poland
-
Karen Doolittle
MBA | PfMP, PgMP, PMP Pharmacovigilance Operations
Updates
-
If you had COVID in June or July during the recent summer surge, you should still get an updated vaccine this fall – and now’s the perfect time! The CDC recommends waiting 3 months after symptoms or a positive test before getting your updated #COVID19 vaccine. Read more: https://lnkd.in/ej6GZYrD
-
We are honored to be named a Science Careers Top Employer for the 10th consecutive year! 🏆🎉 This milestone is not just an accolade—it reflects the passion, dedication, and innovation that our people bring to work each day. Learn more about the recognition here: https://lnkd.in/e_VF9j_q #SCTopEmployers
-
Dan Carroll joined Moderna in January 2023, bringing years of experience in pharmaceutical marketing and a deep commitment to improving public health. As Global Franchise Leader for Vaccines, Dan oversees the global marketing strategies and market research initiatives for Moderna’s vaccine programs. From raising awareness about underrecognized diseases to building new markets, Dan leads with a focus on learning, collaboration, and making a real impact on public health. Learn more about how Dan and his team are shaping the future of vaccines: https://lnkd.in/epv6rXUf
-
In Europe, approved mRNA-based medicines are classified under the same regulatory framework as gene therapies, even though they do not alter human DNA. 🧬 Why? Because #mRNA, as a new platform, doesn't yet have its own regulatory category. As a result, European regulators defaulted to classifying mRNA with other biologicals under gene therapy. But is this classification precise, and does it truly reflect the #science? Why does this matter? Current legislation—developed before mRNA breakthroughs—could cause confusion and slow scientific progress. How we define new technologies directly impacts public trust and acceptance. 📖 Read more about how updated definitions could streamline regulations and help boost public acceptance: https://lnkd.in/eRtb5eM6
-
#ICYMI: During the summer surge, if you had COVID in July or earlier - now’s the perfect time to get your updated #vaccine! The CDC recommends waiting 3 months after symptoms or a positive test before getting your updated #COVID19 vaccine. Protect yourself and your loved ones – find a vaccine near you: http://foryouandthem.com
-
We're back at HLTH Inc.! Stop by the Impact Stage on Oct. 21st to hear our Senior Director of Vaccine Access and Partnerships Hamilton Bennett discuss accelerating #vaccine development, and the Gallery Stage on Oct. 22nd to hear our Executive Director of AI Engineering Andrew Giessel discuss AI’s role in pharmaceutical research. #HLTH2024 #HLTHUSA https://lnkd.in/e4UpTp6k
Agenda | HLTH 2024 | October 20-23, 2024 | Las Vegas - HLTH
hlth.com
-
Today is the start of IDWeek 2024, one of the leading infectious disease conferences in the world. Every year, Moderna looks forward to several days of learning, engaging with infectious disease scientists and experts, and collaborating with leaders in the infectious disease field. Learn more about our presentations at #IDWeek2024: https://lnkd.in/ehVK4-c6
-
School is in full swing, the leaves are turning, and the Halloween candy has hit the shelves. But as the weather cools down, the risk of getting sick is rising – and not just for our kids with the exposure that comes from school. What might be a run-of-the-mill respiratory illness for you and your kids could be severe for your aging parents. Learn more about how you can help keep your loved ones safe, healthy, and able to enjoy time with family during the upcoming holidays: https://lnkd.in/gz95EYF6
-
Respiratory syncytial virus, or RSV, is a respiratory virus so widespread that most children will have been infected with it by the age of two. As a common and highly contagious seasonal virus, RSV is a leading cause of lower respiratory tract infections and can also be dangerous for high-risk adults and those over the age of 60. This #RSVAwarenessMonth, make sure you have the tools and information you need to keep yourself and your community safe: https://lnkd.in/edRSSnTg